Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cemiplimab + VSV-hIFNbeta-NIS|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation (FDA.gov).|
|VSV-hIFNbeta-NIS||Voyager-V1||VSV-hIFNbeta-NIS is oncolytic vesticular stomatitis virus engineered to express human interferon-beta (hIFN-beta) and sodium iodide symporter (NIS), which may inhibit tumor growth (PMID: 26712908, PMID: 22425894).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04291105||Phase II||Cemiplimab + VSV-hIFNbeta-NIS||Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients||Recruiting|